pSivida (PSDV) PT Set at $5.00 by HC Wainwright
A number of other equities analysts have also recently commented on PSDV. B. Riley set a $5.00 price target on pSivida and gave the stock a buy rating in a report on Friday, December 15th. ValuEngine cut pSivida from a sell rating to a strong sell rating in a report on Friday, December 1st. Laidlaw began coverage on pSivida in a report on Wednesday, November 8th. They set a buy rating and a $5.00 price target for the company. Finally, Northland Securities reiterated a buy rating and set a $10.00 price target on shares of pSivida in a report on Monday, December 11th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. The stock currently has an average rating of Buy and an average target price of $7.57.
Shares of pSivida (NASDAQ PSDV) traded down $0.10 during midday trading on Thursday, hitting $0.97. The stock had a trading volume of 346,857 shares, compared to its average volume of 416,582. The company has a market cap of $46.61, a PE ratio of -1.75 and a beta of 1.26. pSivida has a 12 month low of $0.93 and a 12 month high of $2.45.
A hedge fund recently bought a new stake in pSivida stock. Essex Investment Management Co. LLC acquired a new position in shares of pSivida Corp. (NASDAQ:PSDV) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 160,612 shares of the company’s stock, valued at approximately $173,000. Essex Investment Management Co. LLC owned 0.35% of pSivida as of its most recent SEC filing. Institutional investors and hedge funds own 9.70% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.dailypolitical.com/2018/02/09/psivida-psdv-pt-set-at-5-00-by-hc-wainwright.html.
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.
Receive News & Ratings for pSivida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida and related companies with MarketBeat.com's FREE daily email newsletter.